As of 2024-12-14, the Relative Valuation of Fusion Antibodies PLC (FAB.L) is (42.47) GBP. This relative valuation is based on P/E multiples. With the latest stock price at 6.45 GBP, the upside of Fusion Antibodies PLC based on Relative Valuation is -758.4%.
The range of the Relative Valuation is (46.49) - (56.27) GBP.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.1x - 35.5x | 24.4x |
| Forward P/E multiples | 15.7x - 26.7x | 15.9x |
| Fair Price | (46.49) - (56.27) | (42.47) |
| Upside | -820.8% - -972.4% | -758.4% |
| Date | P/E |
| 2024-12-13 | -3.06 |
| 2024-12-12 | -3.37 |
| 2024-12-11 | -3.23 |
| 2024-12-10 | -2.87 |
| 2024-12-09 | -2.89 |
| 2024-12-06 | -2.51 |
| 2024-12-05 | -2.59 |
| 2024-12-04 | -2.78 |
| 2024-12-03 | -1.99 |
| 2024-12-02 | -1.99 |
| 2024-11-29 | -2.02 |
| 2024-11-28 | -2.04 |
| 2024-11-27 | -2.04 |
| 2024-11-26 | -2.04 |
| 2024-11-25 | -2.02 |
| 2024-11-22 | -2.02 |
| 2024-11-21 | -1.99 |
| 2024-11-20 | -2.02 |
| 2024-11-19 | -1.98 |
| 2024-11-18 | -2.18 |
| 2024-11-15 | -2.04 |
| 2024-11-14 | -1.97 |
| 2024-11-13 | -1.90 |
| 2024-11-12 | -1.92 |
| 2024-11-11 | -1.97 |
| 2024-11-08 | -1.97 |
| 2024-11-07 | -1.95 |
| 2024-11-06 | -1.99 |
| 2024-11-05 | -2.02 |
| 2024-11-04 | -2.02 |
| 2024-11-01 | -1.99 |
| 2024-10-31 | -1.99 |
| 2024-10-30 | -1.99 |
| 2024-10-29 | -2.04 |
| 2024-10-28 | -2.02 |
| 2024-10-25 | -1.95 |
| 2024-10-24 | -1.90 |
| 2024-10-23 | -1.90 |
| 2024-10-22 | -1.90 |
| 2024-10-21 | -1.92 |
| 2024-10-18 | -1.99 |
| 2024-10-17 | -2.04 |
| 2024-10-16 | -2.33 |
| 2024-10-15 | -1.97 |
| 2024-10-14 | -1.97 |
| 2024-10-11 | -2.02 |
| 2024-10-10 | -2.02 |
| 2024-10-09 | -2.02 |
| 2024-10-08 | -2.04 |
| 2024-10-07 | -1.92 |